BiotechTube

Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

End-Stage Renal Disease (ESRD)

Conditions

End-Stage Renal Disease (ESRD)

Trial Timeline

Aug 1, 2007 → Jan 1, 2010

NCT ID
NCT00548249

About Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate

Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate is a phase 2 stage product being developed by Rockwell Medical for End-Stage Renal Disease (ESRD). The current trial status is completed. This product is registered under clinical trial identifier NCT00548249. Target conditions include End-Stage Renal Disease (ESRD).

What happened to similar drugs?

8 of 9 similar drugs in End-Stage Renal Disease (ESRD) were approved

Approved (8) Terminated (0) Active (1)
✅donepezil HCl + donepezil HClEisaiApproved
✅Zepatier + Ribavirin + SofosbuvirMerckApproved
✅Anti-Thymocyte Globulin vs Campath-1H vs DaclizumabRocheApproved
✅RanolazineGilead SciencesApproved
✅Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisoneSanofiApproved
✅rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimusSanofiApproved
✅Pioglitazone + placebo comparatorBaxterApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00548249Phase 2Completed

Competing Products

20 competing products in End-Stage Renal Disease (ESRD)

See all competitors
ProductCompanyStageHype Score
Conversion to Advagraf + conversion of non-immunosuppressant drugs to once daily + Conversion to once daily MPAAstellas PharmaPre-clinical
30
donepezil HCl + donepezil HClEisaiApproved
43
paricalcitolAbbViePhase 3
40
daptomycin + daptomycinMerckPhase 1
29
Letermovir 480 mg [PREVYMIS]MerckPhase 1
36
MK-2060 + PlaceboMerckPhase 2
35
Zepatier + Ribavirin + SofosbuvirMerckApproved
43
MK-2060 + PlaceboMerckPhase 1
29
daptomycinMerckPhase 1
29
MK-2060MerckPhase 1
29
MK-2060 + PlaceboMerckPhase 1
29
Anti-Thymocyte Globulin vs Campath-1H vs DaclizumabRocheApproved
43
AvacopanAmgenPhase 1
29
RanolazineGilead SciencesApproved
43
Bosutinib + Bosutinib + Bosutinib + BosutinibPfizerPhase 1
29
CP-690,550PfizerPhase 1
29
BelataceptBristol Myers SquibbPre-clinical
26
Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisoneSanofiApproved
43
Single-dose rabbit Anti-thymocyte Globulin induction + Divided-dose rabbit Anti-thymocyte Globulin inductionSanofiPhase 2
35
rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimusSanofiApproved
43